Intensive Care, Amsterdam UMC - location AMC, University of Amsterdam, Amsterdam, The Netherlands
Laboratory of Intensive Care and Anesthesiology Amsterdam UMC - location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Eur Respir Rev. 2021 Feb 2;30(159). doi: 10.1183/16000617.0317-2020. Print 2021 Mar 31.
Acute respiratory distress syndrome (ARDS) is a devastating critical illness that can be triggered by a wide range of insults and remains associated with a high mortality of around 40%. The search for targeted treatment for ARDS has been disappointing, possibly due to the enormous heterogeneity within the syndrome. In this perspective from the European Respiratory Society research seminar on "Precision medicine in ARDS", we will summarise the current evidence for heterogeneity, explore the evidence in favour of precision medicine and provide a roadmap for further research in ARDS. There is evident variation in the presentation of ARDS on three distinct levels: 1) aetiological; 2) physiological and 3) biological, which leads us to the conclusion that there is no typical ARDS. The lack of a common presentation implies that intervention studies in patients with ARDS need to be phenotype aware and apply a precision medicine approach in order to avoid the lack of success in therapeutic trials that we faced in recent decades. Deeper phenotyping and integrative analysis of the sources of variation might result in identification of additional treatable traits that represent specific pathobiological mechanisms, or so-called endotypes.
急性呼吸窘迫综合征(ARDS)是一种严重的危重病,可由多种损伤引发,其死亡率仍高达约 40%。针对 ARDS 的靶向治疗研究一直令人失望,这可能是由于该综合征存在巨大的异质性。在欧洲呼吸学会关于“ARDS 精准医学”的研究研讨会上的这篇观点文章中,我们将总结目前关于异质性的证据,探讨支持精准医学的证据,并为 ARDS 的进一步研究提供路线图。ARDS 在三个不同层面上表现出明显的差异:1)病因学;2)生理学和 3)生物学,这使我们得出结论,没有典型的 ARDS。缺乏共同的表现意味着 ARDS 患者的干预研究需要注意表型,并采用精准医学方法,以避免我们在近几十年的治疗试验中面临的缺乏成功的情况。更深入的表型分析和对变异来源的综合分析可能会导致发现更多可治疗的特征,这些特征代表特定的病理生物学机制,即所谓的“表型”。